Nirmatrelvir (Paxlovid) Solid Forms
COVID-19
DevelopmentActive
Key Facts
About XtalPi
Founded in 2014 by MIT physicists, XtalPi has evolved from a pioneer in crystal structure prediction (CSP) into a comprehensive AI and automation platform for drug discovery. The company leverages a proprietary 'Hybrid AI + QM Discovery Engine' that combines quantum mechanics, machine learning, and robotic labs to design, predict, and synthesize novel drug candidates with high efficiency. With over 80 partners in pharma and biotech, a team of 1000+ employees, and a proven track record including contributions to Paxlovid's development, XtalPi is positioned as a key technology enabler in the rapidly growing AI-driven drug discovery sector.
View full company profileOther COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |